NCT02699463

Brief Summary

The investigators wish to prospectively determine the response to CPAP in patients presenting with mild OSA. In many healthcare systems, patients with mild OSA (AHI 5-15) are not reimbursed for treatment. Although some evidence exists of the benefits of treating mild OSA when scoring as per AASM 2007 criteria, more evidence is needed. The investigators wish to add to this pool of knowledge and also increase the inclusion criteria to include the AASM 2012 definition of mild OSA. By including the 2012 AASM definition of mild OSA, the investigators will add novel information to the field by assessing the benefits of treatment in both sub-groups of mild OSA.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
301

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2016

Typical duration for not_applicable

Geographic Reach
1 country

11 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 4, 2016

Completed
9 months until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2019

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

January 26, 2021

Completed
Last Updated

January 26, 2021

Status Verified

January 1, 2021

Enrollment Period

2.4 years

First QC Date

March 1, 2016

Results QC Date

December 4, 2020

Last Update Submit

January 6, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Quality of Life Using the Energy and Vitality Subscale of the Short Form 36 (SF-36) Questionnaire

    The Short Form 36 (SF-36) questionnaire measures quality of life through a range of questions asking about patients physical and mental functioning. Specifically, the Energy and Vitality subscale records patients perceptions of their levels of energy and fatigue. Participants were administered the Short Form 36 (SF-36) questionnaire at baseline and 3 months. The change in score (value at 3 months minus value at baseline) was compared between the CPAP group and the Control group. In the SF-36 Energy and Vitality subscale, an increase in score indicates improvement, with a minimum score of 0 and a maximum score of 100 possible.

    3 months

Study Arms (2)

Continous Positive Airway Pressure

ACTIVE COMPARATOR

Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial

Device: Continous Positive Airway Pressure

Control Group

PLACEBO COMPARATOR

Participants will receive standard care (Sleep hygiene counseling) during the study.

Other: Control Group

Interventions

CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA

Also known as: CPAP
Continous Positive Airway Pressure

Standard sleep hygiene counseling as per published guidelines

Control Group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged ≥ 18 and ≤ 80
  • Ability and willingness to provide written informed consent
  • AHI ≤ 15 as per AASM 2007 scoring criteria
  • Ability to tolerate a CPAP one hour long run in test

You may not qualify if:

  • The presence of unstable cardiac disease
  • Inability to give fully informed consent
  • Supplemental oxygen
  • Secondary sleep pathology e.g. Periodic Limb Movement Syndrome, Narcolepsy, Circadian Disorder, obesity hypoventilation syndrome
  • ESS ≥ 15, or concerns about sleepy driving from physician/ sleep lab staff
  • BMI ≥ 40

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

Freeman Hospital

Newcastle upon Tyne, Newcastle, United Kingdom

Location

Blackpool Teaching Hospital

Blackpool, United Kingdom

Location

Papworth Hospital

Cambridge, United Kingdom

Location

Tayside Health Board, Ninewells Hospital

Dundee, United Kingdom

Location

Aintree University Hospital

Liverpool, United Kingdom

Location

Royal Brompton Hospital, Imperial College London

London, SW3 6NP, United Kingdom

Location

Guys & St Thomas Hospital

London, United Kingdom

Location

Oxford Centre for Respiratory Medicine

Oxford, United Kingdom

Location

Derriford Hospital

Plymouth, United Kingdom

Location

Lister Hospital

Stevenage, United Kingdom

Location

Taunton and Somerset Hospital

Taunton, United Kingdom

Location

Related Publications (1)

  • Wimms AJ, Kelly JL, Turnbull CD, McMillan A, Craig SE, O'Reilly JF, Nickol AH, Hedley EL, Decker MD, Willes LA, Calverley PMA, Benjafield AV, Stradling JR, Morrell MJ; MERGE trial investigators. Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial. Lancet Respir Med. 2020 Apr;8(4):349-358. doi: 10.1016/S2213-2600(19)30402-3. Epub 2019 Dec 2.

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Results Point of Contact

Title
Dr Alison Wimms
Organization
ResMed Ltd

Study Officials

  • Mary Morrell, Prof

    Imperial College London

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2016

First Posted

March 4, 2016

Study Start

December 1, 2016

Primary Completion

May 1, 2019

Study Completion

August 1, 2019

Last Updated

January 26, 2021

Results First Posted

January 26, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will not share

Locations